South Africa has unleashed a revolutionary weapon against HIV. On October 21, 2025, the South African Health Products Regulatory Authority (SAHPRA) approved lenacapavir, a long-acting injection providing six months of protection with a single shot. Hailed as a “game-changer” by Health Minister Dr. Aaron Motsoaledi, this marks the first registration of twice-yearly PrEP in Africa, targeting communities where daily pills often fail.
Forget daily routines. Lenacapavir, from Gilead Sciences, delivers near-100% protection against sexual HIV acquisition. With South Africa carrying 13% of global cases, this injection could slash new infections in high-risk groups like young women and sex workers.
Why Lenacapavir Redefines PrEP
Unlike daily oral PrEP such as Truvada, lenacapavir is a subcutaneous injection every six months. As a capsid inhibitor, it blocks HIV from entering CD4 cells. The PURPOSE 1 trial showed 100% efficacy in cisgender women; PURPOSE 2 achieved 96% across diverse groups, including men who have sex with men.
Treatment begins with two injections one month apart plus oral tablets, then maintenance every six months. Side effects are mild—mainly injection-site redness or swelling—and it is safe for pregnant or breastfeeding individuals, vital in high-risk settings.
SAHPRA’s Swift Approval Triumph
SAHPRA approved lenacapavir in just eight months after Gilead’s March 2025 submission, leveraging the European Medicines Agency’s EU-M4all pathway. CEO Dr. Boitumelo Semete-Makokotlela called it “the most effective HIV prevention tool to date.” Local trials by the Desmond Tutu Health Foundation paved the way.
Distinct from cabotegravir (registered in 2022 but not yet rolled out), lenacapavir’s longer interval tackles adherence barriers. Free daily PrEP uptake sits at ~40% due to stigma and forgetfulness—this changes everything.
Priority for High-Risk Groups
Adolescent girls and young women face disproportionate risk, comprising 25% of new infections despite being 10% of the population. Sex workers, men who have sex with men, and pregnant individuals top the rollout list. “Targeting these groups will maximize impact,” says Minister Motsoaledi.
Phased rollout starts April 2026 across 360 clinics in 23 high-burden districts, reaching 450,000 people in year one. Global Fund support keeps costs at $40–60 per person annually—cheaper long-term than treating new cases.
Global Trail from FDA to SAHPRA
The US FDA approved lenacapavir (as Sunlenca for treatment) earlier; PrEP nod came via trials. EMA followed in September 2025. SAHPRA built on these for rapid action. Cabotegravir set the precedent with 2021 FDA approval and 99% real-world efficacy.
BRICS Collaboration Boost
South Africa’s approval strengthens BRICS health ties. Partners with rising HIV burdens eye lenacapavir through shared frameworks. Indian generics from 2027 will cut costs, enabling wider access across emerging economies.
Experts from Médecins Sans Frontières urge accelerated plans continent-wide. South Africa’s lead inspires: “A vital step forward.”
Lenacapavir vs. Cabotegravir
Both outperform pills; lenacapavir wins on convenience. South Africa plans to offer both, letting users choose.
| Feature | Lenacapavir | Cabotegravir |
| Dosing | Every 6 months (subcutaneous) | Every 2 months (intramuscular) |
| Efficacy | 96–100% | 91–99% |
| SA Status | Approved Oct 2025 | Registered 2022 |
| Cost/Year | $40–60 | TBD |
Toward an HIV-Free Future
With guidelines, reminder tools, and community outreach in development, South Africa is poised to curb HIV’s spread. Generics by 2027 ensure sustainability. This approval injects hope—twice yearly—for generations.
The super-jab era has begun.